What is InteloMed?
InteloMed is at the forefront of redefining patient care standards through its intelligent, multi-dimensional, non-invasive CVInsight® Patient Monitoring & Informatics System. This FDA-cleared and CE-marked system provides clinicians with an unprecedented level of real-time, dynamic, and actionable insight into cardiovascular stress and patient tolerance during dialysis. Leveraging patented algorithms, the CVInsight® system offers clinician-set alerts, enabling timely interventions to prevent serious patient consequences and treatment interruptions. The company is headquartered in Wexford, PA., and has already launched its solution commercially in the United States.
How much funding has InteloMed raised?
InteloMed has raised a total of $16.7M across 7 funding rounds:
Private Equity
$2.6M
Series A
$4M
Private Equity
$3.8M
Private Equity
$1.9M
Debt
$502K
Debt
$47K
Other Financing Round
$3.8M
Private Equity (2011): $2.6M, investors not publicly disclosed
Series A (2013): $4M, investors not publicly disclosed
Private Equity (2014): $3.8M, investors not publicly disclosed
Private Equity (2016): $1.9M, investors not publicly disclosed
Debt (2016): $502K, investors not publicly disclosed
Debt (2021): $47K with participation from PPP
Other Financing Round (2025): $3.8M, investors not publicly disclosed
What's next for InteloMed?
The recent major strategic investment in InteloMed, alongside its substantial total funding of $16.7M, positions the company for accelerated scaling and market penetration. This capital infusion is expected to fuel further research and development, enhance commercialization efforts, and potentially expand its product offerings within the critical patient monitoring and informatics sector. The company's focus on providing actionable, non-invasive insights suggests a strategic direction towards becoming a leader in data-driven healthcare solutions, aiming to improve patient outcomes and operational efficiencies in clinical settings.
See full InteloMed company page
